TP53 and colorectal cancer: These results might also explain why immunohistochemistry of p53 is not always associated with survival benefit in colorectal cancer patients treated with 5-FU based chemotherapy (Van Triest et al, 2000), although the lack of relationship with clinical outcome may also be related to the discrepancy between p53 immunostaining and mutation analysis (Momand et al, 1992).